Guarda Maat Nuda: Foto e Video Aggiornati

MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract

MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024

MaaT's phase 3 GvHD trial hits goal, teeing up microbiome filing if cash crunch clears

MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2026

MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology

MaaT microbiota drug shows survival advantage in GvHD

Maat Pharma SA MAAT

Maat (Atenolol) Drug Price and Information

MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan

MaaT Pharma : Pioneering microbiome-driven therapy as new pillar in oncology

AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology

A simple memory technique helped chemotherapy patients stay mentally sharp during treatment

MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe

MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results

Lisbon’s MAAT Museum Heralds New Era for Contemporary Art in Portugal

Zindagi Gulzar Hai to end: What the replacement show ‘Maat’ is all about

MaaT Pharma to Hold Annual General Meeting on June 16, 2026

MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress

Is MaaT back? After 18 months on hold, microbiome biotech sees end to impasse with FDA

MaaT, eyeing 2026 launch for microbiome therapy, posts 18-month data in aGvHD

MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

Availability of MaaT Pharma’s 2024 Universal Registration Document (URD)